• Теги
    • избранные теги
    • Компании2286
      • Показать ещё
      • Показать ещё
      Страны / Регионы354
      • Показать ещё
      • Показать ещё
      Международные организации23
      • Показать ещё
      • Показать ещё
      • Показать ещё
20 января, 22:52

Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?

Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report fourth-quarter and full year 2016 results on Jan 25.

Выбор редакции
20 января, 16:17

Allergan (AGN) Rhofade Cream for Rosacea Approved in U.S.

Allergan plc (AGN) announced that the FDA has approved Rhofade (oxymetazoline hydrochloride) cream for topical treatment of persistent facial erythema (redness) associated with rosacea in adults.

19 января, 17:30

Should Value Investors Choose Allergan (AGN)?

Allergan (AGN) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.

19 января, 17:04

Apricus (APRI) Stock Gains on Vitaros' Approval in Mexico

Apricus (APRI) announced that Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

19 января, 16:40

Biogen (BIIB) Q4 Earnings: What's in Store for the Stock?

Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26.

19 января, 16:37

Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?

We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.

Выбор редакции
19 января, 16:01

Allergan says its cream for facial redness was approved by the FDA

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

19 января, 00:22

Allergan's Uterine Fibroids Candidate Positive in Phase III

Allergan Plc (AGN) and European specialty pharma company Gedeon Richter reported encouraging results from a phase III study on their pipeline candidate, ulipristal acetate, in women with abnormal bleeding due to uterine fibroids.

Выбор редакции
Выбор редакции
13 января, 15:09

Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit

Eli Lilly and Company (LLY) announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited (TEVA) related to the infringement of a vitamin regimen patent for its cancer drug Alimta.

13 января, 14:02

Pharma Stock Roundup: Trump Targets Pharma Again, Merck Up on Keytruda News

The sector was once again slammed by president-elect Donald Trump's comments this week regarding drug pricing.

12 января, 15:15

Deja Vu for Drug Stocks as Trump Slams Drug Pricing Again

Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.

Выбор редакции
Выбор редакции
Выбор редакции
09 января, 17:47

Potential Breakthrough Option For Parkinson's: LTI Partners With Allergan

Today Allergan announced a transformative deal with Lysosomal Therapeutics (LTI), an emerging biotech focused on Parkinson’s Disease through an understanding of human genetics and sphingolipid biology (here). This deal brings a new chapter for LTI as the company moves its lead program into the clinic in 2017. (For full disclosure, Atlas [...]

Выбор редакции
09 января, 16:11

Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

Выбор редакции
09 января, 15:39

Teva Falls on Disappointing 2017 Sales & Earnings Guidance

Teva Pharmaceutical Industries Ltd. (TEVA) provided a weaker-than-expected sales and earnings guidance for 2017, seeing that its blockbuster multiple sclerosis drug, Copaxone, is reeling under competitive pressures.

06 января, 15:24

Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

Выбор редакции
05 января, 16:16

Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.

Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.